Page 7«..6789..2030..»

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

By Dr. Matthew Watson

SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 3:00 p.m. ET.

See original here:
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

To Read More: ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
categoriaGlobal News Feed commentoComments Off on ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit | dataFebruary 15th, 2024
Read All

Lowell Farms Inc. Appoints Jamie Schniedwind as Chief Financial Officer

By Dr. Matthew Watson

SALINAS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born cannabis company with advanced production capabilities including extraction, manufacturing, and distribution, announces the appointment of Jamie Schniedwind as Chief Financial Officer of the Company, effective February 16, 2024.

Read more here:
Lowell Farms Inc. Appoints Jamie Schniedwind as Chief Financial Officer

To Read More: Lowell Farms Inc. Appoints Jamie Schniedwind as Chief Financial Officer
categoriaGlobal News Feed commentoComments Off on Lowell Farms Inc. Appoints Jamie Schniedwind as Chief Financial Officer | dataFebruary 15th, 2024
Read All

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With…

By Dr. Matthew Watson

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor® (rexlemestrocel-L) an Orphan-Drug Designation (ODD) following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition. This follows the Rare Pediatric Disease Designation (RPDD) granted by FDA last month.

Here is the original post:
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With...

To Read More: United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With…
categoriaGlobal News Feed commentoComments Off on United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With… | dataFebruary 15th, 2024
Read All

CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant

By Dr. Matthew Watson

CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant

Read more from the original source:
CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant

To Read More: CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant
categoriaGlobal News Feed commentoComments Off on CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world’s first PET biorecycling plant | dataFebruary 15th, 2024
Read All

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

By Dr. Matthew Watson

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

See the original post:
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

To Read More: Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
categoriaGlobal News Feed commentoComments Off on Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance | dataFebruary 15th, 2024
Read All

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

By Dr. Matthew Watson

LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Read the original:
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

To Read More: Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
categoriaGlobal News Feed commentoComments Off on Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update | dataFebruary 15th, 2024
Read All

3D printing and material processing combined to create artificial bone – Optics.org

By daniellenierenberg

3D printing and material processing combined to create artificial bone  Optics.org

Read the rest here:
3D printing and material processing combined to create artificial bone - Optics.org

To Read More: 3D printing and material processing combined to create artificial bone – Optics.org
categoriaBone Marrow Stem Cells commentoComments Off on 3D printing and material processing combined to create artificial bone – Optics.org | dataFebruary 15th, 2024
Read All

City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia … – StreetInsider.com

By daniellenierenberg

City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia ...  StreetInsider.com

See the original post:
City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia ... - StreetInsider.com

To Read More: City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia … – StreetInsider.com
categoriaBone Marrow Stem Cells commentoComments Off on City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia … – StreetInsider.com | dataFebruary 15th, 2024
Read All

Hematopoietic Stem Cells and Their Role in Development and Disease Therapy – The Scientist

By daniellenierenberg

Hematopoietic Stem Cells and Their Role in Development and Disease Therapy  The Scientist

Read the rest here:
Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist

To Read More: Hematopoietic Stem Cells and Their Role in Development and Disease Therapy – The Scientist
categoriaBone Marrow Stem Cells commentoComments Off on Hematopoietic Stem Cells and Their Role in Development and Disease Therapy – The Scientist | dataFebruary 15th, 2024
Read All

Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure – Phys.org

By daniellenierenberg

Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure  Phys.org

Read this article:
Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure - Phys.org

To Read More: Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure – Phys.org
categoriaBone Marrow Stem Cells commentoComments Off on Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure – Phys.org | dataFebruary 15th, 2024
Read All

Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant… – The Sun

By daniellenierenberg

Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant...  The Sun

Excerpt from:
Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant... - The Sun

To Read More: Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant… – The Sun
categoriaBone Marrow Stem Cells commentoComments Off on Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant… – The Sun | dataFebruary 15th, 2024
Read All

Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual…

By Dr. Matthew Watson

New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy

Read the original here:
Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual...

To Read More: Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual…
categoriaGlobal News Feed commentoComments Off on Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual… | dataFebruary 7th, 2024
Read All

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

By Dr. Matthew Watson

NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

Go here to read the rest:
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

To Read More: Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
categoriaGlobal News Feed commentoComments Off on Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | dataFebruary 7th, 2024
Read All

Virbac : Declaration of the number of shares and voting rights 01/2024

By Dr. Matthew Watson

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

Go here to see the original:
Virbac : Declaration of the number of shares and voting rights 01/2024

To Read More: Virbac : Declaration of the number of shares and voting rights 01/2024
categoriaGlobal News Feed commentoComments Off on Virbac : Declaration of the number of shares and voting rights 01/2024 | dataFebruary 7th, 2024
Read All

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

WESTLAKE VILLAGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 33,750 restricted stock units of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of February 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more here:
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

To Read More: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | dataFebruary 7th, 2024
Read All

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

By Dr. Matthew Watson

HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 9:00 a.m. ET.

Follow this link:
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

To Read More: Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
categoriaGlobal News Feed commentoComments Off on Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | dataFebruary 7th, 2024
Read All

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

CONSHOHOCKEN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees, in each case with a grant date of February 1, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

See the article here:
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

To Read More: Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | dataFebruary 7th, 2024
Read All

Regeneron Announces Investor Conference Presentations

By Dr. Matthew Watson

TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

See the original post:
Regeneron Announces Investor Conference Presentations

To Read More: Regeneron Announces Investor Conference Presentations
categoriaGlobal News Feed commentoComments Off on Regeneron Announces Investor Conference Presentations | dataFebruary 7th, 2024
Read All

Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

By Dr. Matthew Watson

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.

See the article here:
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

To Read More: Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
categoriaGlobal News Feed commentoComments Off on Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference | dataFebruary 7th, 2024
Read All

Sutro Biopharma to Participate in Upcoming Investor Conferences

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.

See the rest here:
Sutro Biopharma to Participate in Upcoming Investor Conferences

To Read More: Sutro Biopharma to Participate in Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Sutro Biopharma to Participate in Upcoming Investor Conferences | dataFebruary 7th, 2024
Read All

Page 7«..6789..2030..»


Copyright :: 2024